Patents Assigned to Medarex, Inc.
  • Methods for characterizing glycosylation sites
    Publication number: 20080299678
    Abstract: The present invention provides methods for isolating and characterizing the glycosylation sites of a glycoprotein, such as a glycosylated antibody. In particular, the methods employ affinity capture, liquid chromatography, and mass spectrometry to determine, for example, the location of the glycopeptide, the heterogeneity of the glycan attached to the glycopeptide, the mass of the glycopeptide, and/or the peptide sequence.
    Type: Application
    Filed: May 16, 2008
    Publication date: December 4, 2008
    Applicant: MEDAREX, INC.
    Inventors: Zhigang Wu, Mohan Srinivasan
  • Cytotoxic Compounds and Conjugates
    Publication number: 20080293800
    Abstract: The present disclosure provides cytoxic compounds useful as drugs or prodrugs and to drug-cleavable substrate conjugates where the drug and cleavable substrate are optionally linked through a self-immolative linker.
    Type: Application
    Filed: November 9, 2006
    Publication date: November 27, 2008
    Applicant: MEDAREX, INC.
    Inventors: Sanjeev Gangwar, Bilal Sufi
  • Human monoclonal antibodies against protective antigen
    Patent number: 7456264
    Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: November 25, 2008
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Israel Lowy, Laura A. Vitale, Diann Blanset, Mohan Srinivasan
  • Methods of treatment using CTLA-4 antibodies
    Patent number: 7452535
    Abstract: The present invention provides method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: November 18, 2008
    Assignee: Medarex, Inc.
    Inventors: Thomas Andrew Davis, Tibor P. Keler, Robert F. Graziano, Alan J. Korman
  • Methods and Compounds For Preparing Cc-1065 Analogs
    Publication number: 20080281102
    Abstract: A method of forming a CBI CC-1065 analog utilizes NH2 as a starting material, where R3 is H or alkyl and R6 is H, substituted or unsubstituted lower alkyl, cyano, or alkoxy. Intermediates (I) are used and are claimed.
    Type: Application
    Filed: October 18, 2006
    Publication date: November 13, 2008
    Applicant: MEDAREX, INC.
    Inventors: Sanjeev Gangwar, Qian Zhang
  • Antibody-Drug Conjugates and Methods of Use
    Publication number: 20080279868
    Abstract: The present disclosure provides antibody-drug conjugates that are potent cytotoxins, wherein the drug is linked to the antibody through a linker. The disclosure is also directed to compositions containing the antibody-drug conjugates, and to methods of treatment using them.
    Type: Application
    Filed: September 26, 2006
    Publication date: November 13, 2008
    Applicant: Medarex, Inc.
    Inventors: Sharon Elaine Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Kilian Horgan, Bilal Sufi, Haichun Huang, David John King, Chin Pan, Josephine M. Cardarelli
  • Therapeutic human anti-IL1-R1 monoclonal antibody
    Patent number: 7438910
    Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: October 21, 2008
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
  • Irta-4 Antibodies and Their Uses
    Publication number: 20080253962
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-4 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-4, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.
    Type: Application
    Filed: September 19, 2005
    Publication date: October 16, 2008
    Applicant: Medarex, Inc
    Inventors: Mohan Srinivasan, Josephine M. Cardarelli, Haichun Huang
  • Prodrug compounds with isoleucine
    Publication number: 20080255248
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Application
    Filed: January 16, 2008
    Publication date: October 16, 2008
    Applicant: MEDAREX, INC.
    Inventors: Lesley B. Pickford, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Geoffrey T. Yarranton
  • USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF TUMORS
    Publication number: 20080226646
    Abstract: The present invention relates to the use of a protein that is differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as a biomolecular target for tumor treatment therapies. The protein is also expressed in tissues from adenocarcinoma, non-melanoma, and renal carcinoma cells. Immunotherapeutic and immunoimaging agents that specifically bind to an identified brain tumor target protein are provided. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
    Type: Application
    Filed: March 10, 2008
    Publication date: September 18, 2008
    Applicant: MEDAREX, INC.
    Inventors: Sabine Mueller, Mirella Gonzalez-Zulueta, Erik Foehr, Daniel J. Chin
  • Monoclonal Antibodies Against The Interferon Receptor, With Neutralizing Activity Against Type I Interferon
    Publication number: 20080226647
    Abstract: The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.
    Type: Application
    Filed: May 9, 2008
    Publication date: September 18, 2008
    Applicant: Medarex, Inc.
    Inventors: Patrick Benoit, Francois Meyer, Deborah Maguire, Ivan Plavec, Michael G. Tovey
  • Enzyme-cleavable prodrug compounds
    Patent number: 7425541
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: September 16, 2008
    Assignee: Medarex, Inc.
    Inventors: Vincent Dubois, Ann Marie Fernandez, Sanjeev Gangwar, Evan Lewis, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey Yarranton
  • Prodrugs activated by plasmin and their use in cancer chemotherapy
    Patent number: 7402556
    Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: July 22, 2008
    Assignee: Medarex, Inc.
    Inventors: André Trouet, Vincent Dubois, Alexandre Passioukov
  • Human monoclonal antibodies against CD30
    Patent number: 7387776
    Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: June 17, 2008
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
  • Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
    Patent number: 7381407
    Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: June 3, 2008
    Assignee: Medarex, Inc.
    Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William Thomas Tino
  • Human monoclonal antibodies to Fc gamma receptor I (CD64)
    Patent number: 7378504
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to CD64 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating autoimmune disorders, transplant rejection, Graft Versus Host Disease, or cancer and for enhanced presentation of antigen using conjugates of an antigen and an anti-CD64 antibody.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: May 27, 2008
    Assignee: Medarex, Inc.
    Inventors: Robert Graziano, Karuna Sundarapandiyan
  • Human monoclonal antibodies against interleukin 8 (IL-8)
    Publication number: 20080118517
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: June 27, 2007
    Publication date: May 22, 2008
    Applicants: MEDAREX, INC., GENMAB A/S
    Inventors: Jessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jorgen Petersen
  • HUMAN ANTI-IFN-GAMMA NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-GAMMA PATHWAY INHIBITORS
    Publication number: 20080107655
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 8, 2008
    Applicants: Amgen Inc., Medarex, Inc.
    Inventors: Andrew Welcher, Hilary Chute, Yue-Sheng Li, Haichun Huang
  • Use of biomolecular targets in the treatment and visualization of tumors
    Patent number: 7368098
    Abstract: The present invention relates to the use of a protein that is differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as a biomolecular target for tumor treatment therapies. The protein is also expressed in tissues from adenocarcinoma, non-melanoma, and renal carcinoma cells. Immunotherapeutic and immunoimaging agents that specifically bind to an identified brain tumor target protein are provided. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: May 6, 2008
    Assignee: Medarex, Inc.
    Inventors: Sabine Mueller, Mirella Gonzalez-Zulueta, Erik Foehr, Daniel J. Chin
  • HUMAN MONOCLONAL ANTIBODIES TO FC GAMMA RECEPTOR L (CD64)
    Publication number: 20080095784
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to CD64 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating autoimmune disorders, transplant rejection, Graft Versus Host Disease, or cancer and for enhanced presentation of antigen using conjugates of an antigen and an anti-CD64 antibody.
    Type: Application
    Filed: June 3, 2005
    Publication date: April 24, 2008
    Applicant: MEDAREX, INC.
    Inventors: Robert Graziano, Karuna Sundarapandiyan